GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Healius Ltd (OTCPK:PHCRF) » Definitions » Notes Receivable

PHCRF (Healius) Notes Receivable : $0 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Healius Notes Receivable?

Healius's Notes Receivable for the quarter that ended in Dec. 2024 was $0 Mil.


Healius Notes Receivable Historical Data

The historical data trend for Healius's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healius Notes Receivable Chart

Healius Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Healius Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Healius Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Healius Notes Receivable Related Terms

Thank you for viewing the detailed overview of Healius's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Healius Business Description

Traded in Other Exchanges
Address
161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging.

Healius Headlines

From GuruFocus

Healius Ltd Conference Call Transcript

By GuruFocus Research 03-29-2024

Full Year 2020 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024

Half Year 2022 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024

David Herro Comments on Primary Health Care

By Holly LaFon Holly LaFon 04-11-2016

Healius Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 03-29-2024

Half Year 2020 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024

Half Year 2021 Healius Ltd Earnings Call Transcript

By GuruFocus Research 03-29-2024

David Herro Comments on Healius

By Sydnee Gatewood Sydnee Gatewood 01-09-2020

Half Year 2024 Healius Ltd Earnings Call Transcript

By GuruFocus Research 02-28-2024